BioSpace News Archive

Business

Former J&J CSO to Lead New Chapter at Galapagos

Galapagos NV has appointed Dr. Paul Stoffelsas as its new chief executive officer, replacing Onno van de Stolpe who is retiring.

January 27, 2022
·
2 min read
·
Vanessa Doctor, RN
Deals

Three Life Sciences Players Up Their Footprint with Manufacturing Expansions

Fujifilm announced that it is acquiring Atara Biotherapeutics’ cell therapy manufacturing facility in California for $100 million.

January 27, 2022
·
3 min read
·
Alex Keown
Business

Septerna Will Take $100M to Unlock Previously Inaccessible GPCRs

Led by Third Rock Ventures, the financing will support Septerna in tapping into new therapeutic areas for G protein-coupled receptor (GPCR) drug targets.

January 27, 2022
·
2 min read
·
Hannah Chudleigh
Drug Development

Merck’s Cancer Blockbuster Keytruda Might Treat HIV Too

The researchers believe Keytruda and possibly other anti-PD-1 checkpoint inhibitors might help the immune system track the last signs of HIV while also preventing HIV’s ability to hide.

January 27, 2022
·
3 min read
·
Mark Terry
Drug Development

Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients

Todos Medical, Ltd. today announced positive interim data for its Tollovir™ oral antiviral 3CL protease inhibitor Phase 2 clinical trial for the treatment of hospitalized (severe and critical) COVID-19 patients.

January 27, 2022
·
14 min read
Business

NeuroSense Therapeutics Extends ALS Biomarker Collaboration with Massachusetts General Hospital

NeuroSense Therapeutics Ltd. announced today the initiation of the third stage of a collaborative biomarker study with Massachusetts General Hospital (MGH).

January 27, 2022
·
6 min read
Numinus Identified as a Licensed Psilocybin Supplier by Health Canada

Numinus Wellness Inc. is pleased to announce that its research facility, Numinus Bioscience, has been included on Health Canada’s list of federally licensed psilocybin producers.

January 27, 2022
·
3 min read
Business

MoMMA’s Voices Awarded New Funding to Further Amplify BIPOC and Other Historically Marginalized Patient Voices in Maternal Health

The Preeclampsia Foundation announced today that Merck for Mothers has awarded new funding for its program, MoMMA’s Voices, a national coalition of patient advocacy organizations and individuals with “lived experience” – or those that represent them.

January 27, 2022
·
2 min read
Drug Development

OS Therapies Announces Nationwide Open Enrollment of Remaining 36 to 42 Patients in Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma

OS Therapies approved open enrollment for AOST-2121: an open label Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma (OS). OS is a deadly and debilitating cancer of the bone that usually occurs in adolescence and young adults (AYA).

January 27, 2022
·
2 min read
Sun Pharma launches (Pr)CEQUA™ (cyclosporine ophthalmic solution 0.09% w/v), the first dry eye treatment with nanomicellar (NCELL™) technology*, in Canada

Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited “Sun Pharma” and includes its subsidiaries and/or associate companies), announced the launch of CEQUA, a new treatment for Canadians living with dry eye disease.

January 27, 2022
·
5 min read